Based on our mechanistic studies here, we would not anticipate the SLE-like and Sjögren’s-like diseases (associated with Act1 deficiency) to be induced in patients under anti-IL-17 therapy. Here, TRAF3IP2 is linked to systemic lupus erythematosus.